Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Prescribing guidelines produced for new anti-rheumatic drugs

Return to PJ Online Home Page

The Pharmaceutical Journal Vol 264 No 7101p903
June 17, 2000 Clinical

Prescribing guidelines produced for new anti-rheumatic drugs

Guidelines setting out how and when to prescribe tumour necrosis factor (TNF) blockers for treating rheumatoid arthritis have been produced by the British Society for Rheumatology.
The BSR says that the guidelines were designed to ensure that new treatments are introduced in a systematic and planned way. They are based on published clinical trial data and cover the two TNF blockers that are currently available, etanercept and infliximab. (Only etanercept is licensed for treating rheumatoid arthritis at present.) They recommend that TNF blockers are only prescribed in secondary care.
In terms of clinical efficacy, the guidelines state: "Although both etanercept and infliximab appear to be more effective than standard therapy, their use cannot be justified in patients who might respond equally well to much cheaper conventional therapy with sulphasalazine or methotrexate with which there is extensive long-term clinical experience." Trials of combination therapy have shown that "methotrexate and TNF blockers are synergistic and the data show that combining the two agents in methotrexate-resistant patients results in a substantial response rate."
The guidelines specify who should be receiving the new drugs. Such patients include those with highly active RA, calculated by a composite disease activity score. Alternatively, patients could have failed on standard therapy for RA. This would involve treatment failure with at least two disease modifying anti-rheumatic agents. The guidelines also specify exclusion criteria for TNF blocker treatment, including pregnancy, breast feeding, patients with or at high risk of infection and patients with malignancy or pre-malignancy states. The guidelines discuss criteria, such as adverse events and inefficacy, for the withdrawal of therapy.
The BSR is advising that a central registry of all patients treated with TNF blockers is set up in order to monitor use, benefit and side effects of the drugs. It will study both the short- and long-term toxicity of these drugs, in particular the incidence of serious infections, the development of malignancies and mortality.
Infections have been seen in the US, mostly in patients predisposed to infections, the BSR says. It adds that the mode of action of TNF blockers gives a theoretical risk of immunosuppression and malignancy.
Launching the guidelines on June 8, Dr Andrew Bamji (chair of the working party) said: "If these treatments prove their worth there could be a strong case for increasing the drugs budget. This will mean higher costs at first, but might lead to real savings in the long term. The demand for other expensive services could be dramatically reduced, including fewer joint replacements and less demand for physiotherapy, occupational therapy and podiatry services."
The BSR says that the guidelines will be reviewed and revised as new evidence becomes available and will be posted on the BSR website (http://www.rheumatology.org.uk).

The strategy aims to maintain the effectiveness of antimicrobial agents
The strategy aims to maintain the effectiveness of antimicrobial agents

Citation: The Pharmaceutical Journal URI: 20001852

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Prescribing Adult Intravenous Nutrition

    Prescribing Adult Intravenous Nutrition

    A practical guide to the principles and practice of adult intravenous nutrition. With numerous illustrations and case studies.

    £40.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Rate
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.